Amneal Pharmaceuticals (AMRX)CFO sold ~$1.11M
Tasos Konidaris, CFO at Amneal Pharmaceuticals, sold ~$1.11M of Amneal Pharmaceuticals shares.
- ~$1.11M
- Approx. value · 119K sh @ $9.30
- 341K
- Holds after · shares reported
- Traded
- Aug 14, 2025
- Filed
- Aug 15, 2025
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Jun 16, 2025InsiderDirector sold ~$761K of AMRX shares in the open market
- Aug 12, 2025Insider · 3 peopleInsiders: 3 sales (~$954K)
- Aug 13, 2025InsiderCFO sold ~$1.49M of AMRX shares in the open market
- Aug 14, 2025 · this disclosureInsiderCFO sold ~$1.11M of AMRX shares in the open market
What came next
- Aug 14, 2025InsiderOfficer sold ~$666K of AMRX shares in the open market
- Aug 15, 2025InsiderCFO sold ~$2.07M of AMRX shares in the open market
- Aug 20, 2025InsiderOfficer sold ~$2.62M of AMRX shares in the open market
- Aug 22, 2025InsiderOfficer sold ~$1.11M of AMRX shares in the open market
- Aug 25, 2025InsiderOfficer sold ~$60K of AMRX shares in the open market
- Aug 27, 2025InsiderDirector sold ~$295K of AMRX shares in the open market
- Oct 30, 2025Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Amneal Pharmaceuticals
For Amneal Pharmaceuticals, OQRO holds 2 fund holdings reports (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its AMRX page.
Other recent filings by Tasos Konidaris, Executive Vice President & CFO
- SEC Form 4 at Amneal Pharmaceuticals (AMRX)Aug 15, 2025
- SEC Form 4 at Amneal Pharmaceuticals (AMRX)Aug 15, 2025
- SEC Form 4 at Amneal Pharmaceuticals (AMRX)Mar 7, 2025
The full history of Tasos Konidaris, Executive Vice President & CFO is on the profile page.
How this filing works
Other disclosures at Amneal Pharmaceuticals
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 12, 2026
- SEC Form 13F-HRMay 15, 2026
- SEC Form 13F-HRMay 4, 2026
- SEC Form 13F-HRNov 14, 2025
- SEC Form 4Aug 28, 2025
Everything OQRO holds on this company is on its AMRX page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO Pro is a paid subscription. You see the price before you pay
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
